Perrigo Company plc is a prominent international pharmaceutical and consumer health company that specializes in the development, manufacturing, and distribution of over-the-counter (OTC) consumer healthcare products, generic prescription drugs, and active pharmaceutical ingredients (APIs). The company operates primarily through two main segments: Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). Perrigo's core business model revolves around providing high-quality, value-oriented private-label (store-brand) alternatives to branded medications, partnering with major retailers, supermarkets, and pharmacy chains globally. Its extensive product portfolio covers various therapeutic categories, including upper respiratory (cough, cold, and allergy relief), digestive health, pain management, sleep aids, infant formulas, and topical treatments. Geographically, while Perrigo generates the majority of its revenue in the United States, it maintains a significant presence across Europe, Australia, and other international markets. The company traces its origins to 1887 in Allegan, Michigan, but executed a corporate tax inversion in 2013 by acquiring Elan Corporation, which relocated its legal domicile to Dublin, Ireland, while its operational headquarters remained in Michigan (currently Grand Rapids). Perrigo's competitive advantage lies in its massive scale, vertically integrated supply chain, and regulatory expertise, allowing it to efficiently produce and distribute affordable self-care products that empower consumers to manage their health proactively.
